PD-1 & PD-L1 Inhibitors Market - Global Forecast 2026-2032

PD-1 and PD-L1 inhibitors have transformed cancer care by integrating targeted immunomodulation into standard oncology practice, creating new opportunities and challenges for industry leaders navigating evolving regulatory, supply, and competitive environments.

Market Snapshot: PD-1 & PD-L1 Inhibitors Market

The PD-1 & PD-L1 Inhibitors Market grew from USD 53.91 billion in 2025 to USD 64.53 billion in 2026. It is expected to continue expanding at a CAGR of 21.27%, reaching USD 208.06 billion by 2032. This sustained trajectory highlights the sector's status as a cornerstone of immuno-oncology, with ongoing advances in clinical utility, geographic reach, and technology-driven delivery platforms.

Scope & Segmentation

This report delivers in-depth analysis of all key market segments and dynamics influencing the PD-1 & PD-L1 inhibitors market, enabling stakeholders to identify growth opportunities and optimize strategic planning.

Product Types: PD-1 inhibitors (e.g., nivolumab, pembrolizumab, cemiplimab) and PD-L1 inhibitors (e.g., atezolizumab, avelumab, durvalumab), each with unique clinical characteristics and safety profiles.
Indications: Tumor-specific insights covering bladder cancer, lung cancer, head and neck cancer, melanoma, renal cell carcinoma, and emerging investigational settings.
End Users: Hospitals, research institutes, and specialty clinics, each shaping clinical adoption, delivery, and post-approval evidence generation.
Distribution Channels: Hospital pharmacy, online pharmacy, and retail pharmacy, all relevant to evolving administration routes and outpatient delivery models.
Routes of Administration: Intravenous and subcutaneous formulations, impacting patient throughput, convenience, and site-of-care decision-making.
Geographies: Americas, Europe, Middle East & Africa, and Asia-Pacific, with analysis of local market access, regulatory trends, and manufacturing capacity.
Company Strategies: Approaches of leading developers focusing on R&D, diagnostics integration, manufacturing scale-up, and alliance networks.
Technology Integration: Use of advanced companion diagnostics, biomarker development, and formulation innovations such as fixed-dose and subcutaneous administration.

Key Takeaways

The primary keyword, PD-1 & PD-L1 inhibitors, remains essential for stakeholders across clinical care, translational research, and market access strategy.
Shift from monotherapy to combination regimens and expansion into adjuvant/neoadjuvant settings are redefining trial design and approval pathways.
Product differentiation is driven not just by efficacy, but also by patient convenience, dosing cadence, and associated diagnostics that facilitate precise patient selection.
End users—including hospitals, research institutes, and specialty clinics—have nuanced roles in shaping adoption and administration models due to resource allocation and expertise.
Distribution flexibility is increasingly important, with hospital pharmacies predominant for complex regimens and retail or online channels supporting outpatient or self-administered formats.
Major companies such as AstraZeneca, Merck & Co., Roche, and Bristol-Myers Squibb demonstrate varied strategies in portfolio expansion, real-world evidence generation, diagnostics alignment, and manufacturing innovation.

Tariff Impact

United States tariff adjustments in 2025 have compelled manufacturers and suppliers to reinforce supply chain resilience. Companies are adopting nearshoring strategies, renegotiating contracts, and leveraging bonded logistics to offset increased landed costs and procurement complexity. Hospitals and pharmacy buyers are modifying purchasing protocols and, where feasible, enhancing regional production capabilities to maintain supply continuity amid cost pressures.

Methodology & Data Sources

Research findings integrate primary interviews with clinical experts, payers, procurement leaders, and supply chain executives. Secondary analysis draws from peer-reviewed literature, regulatory updates, and corporate disclosures. Triangulation of qualitative and quantitative inputs enables a rigorous synthesis of trends across products, regions, and end users.

Why This Report Matters

Supports senior decision-makers in optimizing evidence generation, supply chain strategy, and market access across a dynamic immuno-oncology landscape.
Provides actionable segmentation analysis to guide portfolio differentiation and geographic expansion plans in diverse regulatory environments.
Equips leaders with deep insights into evolving clinical paradigms, enabling alignment of commercialization strategy with payer, provider, and patient priorities.

Conclusion

Sustained success in the PD-1 & PD-L1 inhibitors market requires coordinated focus on differentiated clinical value, operational resilience, and targeted commercial innovation. Stakeholders that integrate strategic evidence generation, supply continuity, and flexible distribution will best navigate the demands of a rapidly advancing global landscape.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. PD-1 & PD-L1 Inhibitors Market, by Product Type

8.1. PD-1 Inhibitor
8.1.1. Cemiplimab
8.1.2. Nivolumab
8.1.3. Pembrolizumab
8.2. PD-L1 Inhibitor
8.2.1. Atezolizumab
8.2.2. Avelumab
8.2.3. Durvalumab

9. PD-1 & PD-L1 Inhibitors Market, by Indication

9.1. Bladder Cancer
9.2. Head And Neck Cancer
9.3. Lung Cancer
9.4. Melanoma
9.5. Renal Cell Carcinoma

10. PD-1 & PD-L1 Inhibitors Market, by Route Of Administration

10.1. Intravenous
10.2. Subcutaneous

11. PD-1 & PD-L1 Inhibitors Market, by Company

11.1. AstraZeneca
11.2. Bristol-Myers Squibb
11.3. Merck & Co.
11.4. Roche

12. PD-1 & PD-L1 Inhibitors Market, by End User

12.1. Hospitals
12.2. Research Institutes
12.3. Specialty Clinics

13. PD-1 & PD-L1 Inhibitors Market, by Distribution Channel

13.1. Hospital Pharmacy
13.2. Online Pharmacy
13.3. Retail Pharmacy

14. PD-1 & PD-L1 Inhibitors Market, by Region

14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific

15. PD-1 & PD-L1 Inhibitors Market, by Group

15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO

16. PD-1 & PD-L1 Inhibitors Market, by Country

16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea

17. United States PD-1 & PD-L1 Inhibitors Market
18. China PD-1 & PD-L1 Inhibitors Market

19. Competitive Landscape

19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Akeso Inc
19.6. Amgen Inc
19.7. AstraZeneca plc
19.8. Biocad
19.9. Bristol-Myers Squibb Company
19.10. Coherus BioSciences
19.11. CStone Pharmaceuticals
19.12. Eli Lilly and Company
19.13. F. Hoffmann-La Roche AG
19.14. Gilead Sciences Inc
19.15. GlaxoSmithKline plc
19.16. Henlius Biotech
19.17. Incyte Corporation
19.18. Innovent Biologics Inc
19.19. Jiangsu Hengrui Medicine Co Ltd
19.20. Merck & Co Inc
19.21. Novartis AG
19.22. ONO Pharmaceutical Co Ltd
19.23. Pfizer Inc
19.24. Regeneron Pharmaceuticals Inc
19.25. Shanghai Junshi Biosciences Co Ltd
19.26. Sino Biopharmaceuticals

List of Figures

FIGURE 1. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 91. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 92. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 124. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 125. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 126. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 127. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 128. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2032 (USD MILLION)
TABLE 129. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. EUROPE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 140. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 142. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 143. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 144. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 145. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 146. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2032 (USD MILLION)
TABLE 147. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 148. AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 159. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 161. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 162. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 163. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 164. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 165. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2032 (USD MILLION)
TABLE 166. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. ASEAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 169. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 170. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 171. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 172. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 173. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 174. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2032 (USD MILLION)
TABLE 175. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. GCC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 188. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 189. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 190. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 191. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 192. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2032 (USD MILLION)
TABLE 193. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. BRICS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 195. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 197. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 198. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 199. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 200. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 201. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2032 (USD MILLION)
TABLE 202. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. G7 PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 205. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 206. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 207. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 208. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 209. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 210. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2032 (USD MILLION)
TABLE 211. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 212. NATO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 213. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 214. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 215. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 216. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 217. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 218. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 219. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 220. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2032 (USD MILLION)
TABLE 221. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 222. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 223. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 224. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 225. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 226. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 227. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 228. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 229. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2032 (USD MILLION)
TABLE 230. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 231. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this PD-1 & PD-L1 Inhibitors market report include:

Akeso Inc
Amgen Inc
AstraZeneca plc
Biocad
Bristol-Myers Squibb Company
Coherus BioSciences
CStone Pharmaceuticals
Eli Lilly and Company
F. Hoffmann-La Roche AG
Gilead Sciences Inc
GlaxoSmithKline plc
Henlius Biotech
Incyte Corporation
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
Merck & Co Inc
Novartis AG
ONO Pharmaceutical Co Ltd
Pfizer Inc
Regeneron Pharmaceuticals Inc
Shanghai Junshi Biosciences Co Ltd
Sino Biopharmaceuticals

Table Information

Report Attribute	Details
No. of Pages	198
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 64.53 Billion
Forecasted Market Value ( USD ) by 2032	$ 208.06 Billion
Compound Annual Growth Rate	21.2%
Regions Covered	Global
No. of Companies Mentioned	23

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3513EUR$3,939USD£3,047GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3789EUR$4,249USD£3,286GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5136EUR$5,759USD£4,454GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6215EUR$6,969USD£5,390GBP

Market Snapshot: PD-1 & PD-L1 Inhibitors Market

Scope & Segmentation

Key Takeaways

Tariff Impact

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

PD-1/PD-L1 Inhibitor Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

PD-1 and PD-L1 Inhibitors Market Report and Forecast 2025-2034

PD-1 And PD-L1 Inhibitors - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

PD-1 and PD-L1 Inhibitors Market - Global Strategic Business Report

PD-1 and PD-L1 Inhibitors - Competitive landscape, 2025